Two kinds of endometrial neoplasia arising from different origins in the uterine corpus: Comparison of p53 expression and sex steroid receptor status

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 104, Issue 2, 2002, Pages 167-170

  Koshiyama, Masafumi ^a   Ueta, Michio ^a  

^a NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

Author keywords

Adenomyosis uteri; Clear cell adenocarcinoma; Complex atypical hyperplasia; Estrogen receptor; p53

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53; SEX HORMONE; TUMOR MARKER;

ADENOMYOSIS; AGED; ARTICLE; BLEEDING; CANCER INVASION; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MENOPAUSAL SYNDROME; MYOMETRIUM; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PELVIS LYMPHADENECTOMY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADICAL HYSTERECTOMY; TRANSVAGINAL ECHOGRAPHY; TUMOR VOLUME; UTERUS;

EID: 0037057227     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(02)00104-5     Document Type: Article

References (13)

1. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15:1983;10-17.
2. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's Pathology of the Female Genital Tract. 4th ed. Berlin: Springer, 1994. p. 439-86.
3. Koshiyama M., Konishi I., Fujii S. Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J. 11:1998;277-283.
4. Li S.H., Shiozawa T., Nakayama K., Nikaido T., Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer. 77:1996;321-329.
5. Stewart R.L., Royds J.A., Burton J.L., Heatley M.K., Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology. 33:1998;440-445.
6. Kohler M.F., Berchuck A., Davidoff A.M.et al. Over-expression and mutation of p53 in endometrial carcinoma. Cancer Res. 52:1992;1622-1627.
7. Koshiyama M., Konishi I., Wang D.P.et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinoma: inverse correlation with sex steroid receptor status. Virchows Arch. A Pathol. Anat. 423:1993;265-271.
8. Kohler M.F., Nishii H., Humphrey P.A.et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am. J. Obstet. Gynecol. 169:1993;690-694.
9. Sherman M.E., Bur M.E., Kurman R.J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26:1995;1268-1274.
10. King S.A., Adas A.A., LiVolsi V.A.et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 75:1995;2700-2705.
11. Khalifa M.A., Mannel R.S., Haraway S.D., Walker J., Min K.W. Expression of EGFR, HER-2/neu, p53 and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol. Oncol. 53:1994;84-92.
12. Niwa K., Murase T., Morishita S., Hashimoto M., Itoh N., Tamaya T. p53 overexpression and mutation in endometrial carcinoma, inverse relation with estrogen and progesterone receptor status. Cancer Detect. Prev. 23:1999;147-154.
13. Taskin M., Lallas T.A., Shevchuk M., Barber H.R.K. p53 expression in adenomyosis in endometrial carcinoma patients. Gynecol. Oncol. 62:1996;241-246.